論文

査読有り 国際誌
2019年6月28日

Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.

Cancer letters
  • Youyi Chen
  • I Wayan Sumardika
  • Nahoko Tomonobu
  • I Made Winarsa Ruma
  • Rie Kinoshita
  • Eisaku Kondo
  • Yusuke Inoue
  • Hiroki Sato
  • Akira Yamauchi
  • Hitoshi Murata
  • Ken-Ichi Yamamoto
  • Shuta Tomida
  • Kazuhiko Shien
  • Hiromasa Yamamoto
  • Junichi Soh
  • Ming Liu
  • Junichiro Futami
  • Kaori Sasai
  • Hiroshi Katayama
  • Miyoko Kubo
  • Endy Widya Putranto
  • Toshihiko Hibino
  • Bei Sun
  • Masahiro Nishibori
  • Shinichi Toyooka
  • Masakiyo Sakaguchi
  • 全て表示

452
開始ページ
178
終了ページ
190
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.canlet.2019.03.023

Since metastasis accounts for the majority of cancer-associated deaths, studies on the mechanisms of metastasis are needed to establish innovative strategies for cancer treatment. We previously reported that melanoma cell adhesion molecule (MCAM) functions as a critical receptor for S100A8/A9, and binding of S100A8/A9 to MCAM results in the migration of melanoma cells to lung tissue. However, the critical role of MCAM in the original melanoma skin lesion is still not clear. In this study, we aimed to determine the importance of the S100A8/A9-MCAM axis in melanoma dissemination in a skin lesion as a critical early step for metastasis. Mechanistic studies revealed the downstream signaling of MCAM that signaled the induction of metastasis. S100A8/A9-MCAM binding activates mitogen-activated protein kinase kinase kinase 8 (MAP3K8), also termed TPL2, leading to strong activation of the transcription factor ETV4 and subsequent induction of matrix metalloproteinase-25 (MMP25), and finally to induction of melanoma lung tropic metastasis. Collectively, our results demonstrate a crucial role of the S100A8/A9-MCAM signaling axis in metastatic onset of melanoma cells and indicate that strategies targeting the identified pathway may be useful for the establishment of innovative anti-cancer therapies.

リンク情報
DOI
https://doi.org/10.1016/j.canlet.2019.03.023
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/30904617
ID情報
  • DOI : 10.1016/j.canlet.2019.03.023
  • ISSN : 0304-3835
  • PubMed ID : 30904617

エクスポート
BibTeX RIS